Cardio-oncology

New Cancer Patients

Cancer care saves lives. However, there is mounting evidence that many cancer therapies may cause cardiotoxicity–a condition that damages the heart. As a result, new cancer patients and survivors may be at an increased risk of developing cardiovascular disease.[1]

MyoStrain® provides actionable information to help cardio-oncologists proactively detect and manage the cardiotoxic effects of cancer therapy on the heart without interrupting cancer care. Physicians may be able to use this approach to determine cardio-protective treatment strategies, optimize the effectiveness of protective treatment, and monitor the patient’s heart health throughout cancer therapy.

Cancer Survivors

There are 17 million cancer survivors in the United States, many of whom may not currently be monitored for cardiotoxicity.[2] 30-40% of cancer patients will suffer from progressive heart disease, and 1 in 10 of these patients will experience an adverse cardiac event.[1] Moreover, cancer recurrence is 59% more likely in patients with cardiovascular disease.[3] This highlights the importance for oncologists and cardio-oncologists to continue monitoring their patients’ heart health long after completing cancer remission.

MyoStrain® provides a rapid, non-invasive assessment for physicians to assess the risk for developing cardiovascular disease post-treatment. Through regular follow-up exam, physicians may utilize MyoStrain to monitor changes in heart health over time and protect the heart long-term for improved longevity and quality of life.

Cancer Survivors

There are 17 million cancer survivors in the United States, many of whom may not currently be monitored for cardiotoxicity.[2] 30-40% of cancer patients will suffer from progressive heart disease, and 1 in 10 of these patients will experience an adverse cardiac event.[1] Moreover, cancer recurrence is 59% more likely in patients with cardiovascular disease.[3] This highlights the importance for oncologists and cardio-oncologists to continue monitoring their patients’ heart health long after completing cancer remission.

MyoStrain® provides a rapid, non-invasive assessment for physicians to assess the risk for developing cardiovascular disease post-treatment. Through regular follow-up exam, physicians may utilize MyoStrain to monitor changes in heart health over time and protect the heart long-term for improved longevity and quality of life.

Cancer Survivors

There are 17 million cancer survivors in the United States, many of whom may not currently be monitored for cardiotoxicity.[2] 30-40% of cancer patients will suffer from progressive heart disease, and 1 in 10 of these patients will experience an adverse cardiac event.[1] Moreover, cancer recurrence is 59% more likely in patients with cardiovascular disease.[3] This highlights the importance for oncologists and cardio-oncologists to continue monitoring their patients’ heart health long after completing cancer remission.

MyoStrain® provides a rapid, non-invasive assessment for physicians to assess the risk for developing cardiovascular disease post-treatment. Through regular follow-up exam, physicians may utilize MyoStrain to monitor changes in heart health over time and protect the heart long-term for improved longevity and quality of life.

Cardio-oncology Publications

Multiparametric Early Detection and Prediction of Cardiotoxicity Using Myocardial Strain, T1 and T2 Mapping, and Biochemical Markers: A Longitudinal Cardiac Resonance Imaging Study During 2 Years of Follow-Up
This publication features key outcome data from the PREFECT study demonstrating MyoStrain's ability to help clinicians detect and predict early cardiotoxicity in patients undergoing cancer therapy. These findings highlight MyoStrain as an accurate and sensitive assessment that may enable cardio-oncologists to implement cardio-protective strategies for cancer patients.
This is some text inside of a div block.
Cardio-oncology
June 15, 2021
Circulation: Cardiovascular Imaging
CMR fast-SENC intramyocardial LV & RV segmental strain detects cardiotoxicity during oncology treatment and impact of cardioprotection therapy before echocardiography
This abstract utilizes MyoStrain in the early detection of cardiotoxicity for patients undergoing oncology treatment, as compared to echocardiography. The abstract also examines the effectiveness of cardio-protection, utilizing MyoStrain to monitor and manage the effects of cardioprotective therapy on patient heart function.
This is some text inside of a div block.
Cardio-oncology
August 31, 2019
Abstract at ESC Congress 2019
CMR fast-SENC intramyocardial LV & RV segmental strain helps manage cardioprotective therapy in patients exhibiting cardiotoxicity during cancer treatment
This abstract demonstrates the clinical application of MyoStrain as a tool to help quantify, monitor, and manage cardio-protection for oncology patients exhibiting cardiotoxicity.
This is some text inside of a div block.
Cardio-oncology
August 31, 2019
Abstract at ESC Congress 2019

Chronic Disease Publications

Left and right ventricular strain using fast strain-encoded cardiovascular magnetic resonance for the diagnostic classification of patients with chronic non-ischemic heart failure due to dilated, hypertrophic cardiomyopathy or cardiac amyloidosis
The study compared MyoStrain’s ability to quantify and differentiate asymptomatic patients based on their cardiac risk versus traditional ejection faction, reiterating the technology's potential as a critical cardiac risk stratification tool enabling clinicians to identify at-risk patients early for individualized preventative treatment.
This is some text inside of a div block.
Heart Failure, Chronic Diseases
April 5, 2021
Journal of Cardiovascular Magnetic Resonance
Fast strain-encoded cardiac magnetic resonance for diagnostic classification and risk stratification of heart failure patients
This article demonstrates MyoStrain's ability to identify patients with subclinical LV dysfunction and those at risk for heart failure-related outcomes compared with LVEF, providing an additional diagnostic window for prevention treatments.
This is some text inside of a div block.
Heart Failure, Chronic Diseases
January 13, 2021
JACC Cardiovascular Imaging
Echocardiography and cardiovascular magnetic resonance based evaluation of myocardial strain and relationship with late gadolinium enhancement
This paper evaluates and compares MyoStrain's ability to detect fibrosis based on late gadolinium enhancement versus speckle tracking echocardiography.
This is some text inside of a div block.
Chronic Diseases
August 8, 2019
Journal of Cardiovascular Magnetic Resonance

Stress Testing Publications

Fast-Strain Encoded Cardiac Magnetic Resonance During Vasodilator Perfusion Stress Testing
This study shows MyoStress was non-inferior to CMR stress testing, with a comparable ability to diagnose and risk stratify CAD patients. This test offers advantages in speed, ease and reproducibility, creating an opportunity for a rapid, cost-effective stress test that gives physicians the ability to evaluate patients efficiently.
This is some text inside of a div block.
Stress Testing
November 17, 2021
Frontiers in Cardiovascular Medicine
Feasibility of fast cardiovascular magnetic resonance strain imaging in patients presenting with acute chest pain
This study indicates that in patients presenting with acute chest pain and inconclusive initial clinical screening, MyoStrain can be used to rule out obstructive coronary artery disease. These results show that MyoStrain may serve as a fast and accurate diagnostic tool that could be integrated into clinical workflows.
This is some text inside of a div block.
Stress Testing
May 3, 2021
PLoS ONE
Hyperventilation/Breath-Hold Maneuver to Detect Myocardial Ischemia by Strain-Encoded CMR: Diagnostic Accuracy of a Needle-Free Stress Protocol
This article demonstrates MyoStrain’s speed and sensitivity to successfully measure cardiac stress during a safe, simple hyperventilation breathing maneuver. Performed without any pharmacological or physical stress protocols, this new technique may provide clinicians with a faster and safer quantitative stress test to help improve the diagnosis and management of coronary artery disease.
This is some text inside of a div block.
Stress Testing
April 15, 2021
JACC: Cardiovascular Imaging

Heart Failure Publications

Multiparametric assessment of left ventricular hypertrophy using late gadolinium enhancement, T1 mapping and strain-encoded cardiovascular magnetic resonance
Results from this publication demonstrated MyoStrain’s accuracy and reproducibility for the detection of cardiac dysfunction across multiple disease states. This highlights MyoStrain's clinical utility in identifying patients in need of care based on the extent and severity of subclinical dysfunction.
This is some text inside of a div block.
Heart Failure
July 12, 2021
Journal of Cardiovascular Magnetic Resonance
The impact of Wilson disease on myocardial tissue and function: a cardiovascular magnetic resonance study
This publication showcases MyoStrain’s promising clinical utility as a sensitive tool to detect early heart dysfunction over traditional testing methods, irrespective of disease type.
This is some text inside of a div block.
Heart Failure
June 24, 2021
Journal of Cardiovascular Magnetic Resonance
Left and right ventricular strain using fast strain-encoded cardiovascular magnetic resonance for the diagnostic classification of patients with chronic non-ischemic heart failure due to dilated, hypertrophic cardiomyopathy or cardiac amyloidosis
The study compared MyoStrain’s ability to quantify and differentiate asymptomatic patients based on their cardiac risk versus traditional ejection faction, reiterating the technology's potential as a critical cardiac risk stratification tool enabling clinicians to identify at-risk patients early for individualized preventative treatment.
This is some text inside of a div block.
Heart Failure, Chronic Diseases
April 5, 2021
Journal of Cardiovascular Magnetic Resonance
References

[1] European Society of Cardiology (2019). Cancer patients are at higher risk of dying from heart disease and stroke. https://www.escardio.org/The-ESC/Press-Office/Press-releases/Cancer-patients-are-at-higher-risk-of-dying-from-heart-disease-and-stroke. [2] American Cancer Society (2019). Population of US Cancer Survivors Grows to Nearly 17 Million. https://www.cancer.org/latest-news/population-of-us-cancer-survivors-grows-to-nearly-17-million.html. [3] Bankhead, C. (2020). MI May Fuel Breast Cancer Recurrence, Mortality. Medpage Today. https://www.medpagetoday.com/hematologyoncology/breastcancer/87603?vpass=1.